Harrison Global signs international business partnership agreement with Biotree

Harrison Global (BLMZ) Holdings signed a strategic international business partnership agreement with Biotree. Biotree has completed Phase 1 clinical trials in the United States for PH-100, its natural product-based treatment targeting metabolic syndrome and diabetic complications. Additionally, Biotree has concluded Phase 2A clinical trials across 12 university hospitals in Korea. The Phase 2A clinical trial results confirmed a significant reduction in inflammatory markers and showed positive effects on cardiovascular disease without adverse side effects. Pending the successful completion of the ongoing Phase 2B clinical trials, the drug is expected to be conditionally approved and launch as a prescription-only treatment in the first half of 2026. Among seaweeds, Gamtae stands out for its notable health benefits, including dementia prevention, vascular health support, and anticancer effects – often called the ocean’s natural nutrient. Biotree is the first Korean company to extract “Seapolynol,” a marine polyphenol, from Gamtae, and has since developed and sold a diverse range of products spanning health functional foods, pharmaceuticals, daily necessities, and cosmetics. Biotree has quietly expanded its presence in both domestic and international markets.Harrison Global Holdings plans to actively pursue the global expansion of Biotree’s new drug technology and raw materials for metabolic syndrome treatments, including exports to markets such as the US, Japan, China, and Asia. Under the partnership, the scope of operations includes, but is not limited to: Establishing a joint venture or licensing agreement for operations in local countries Joint development of new natural product drugs and their localization in each country Sharing of branding, distribution channels, and technological infrastructure Cooperation in introducing and developing local partners Regulatory compliance, media strategy, and local PR support.